Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients

Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform

Bafna Pharmaceuticals inaugurates Quality Control Lab

The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes

Takeda receives positive CHMP opinion for Fruquintinib in previously treated mCRC

If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade

Zydus Lifesciences gets 10 observations from USFDA for Jarod injectable facility

The company will closely work with the USFDA to address and respond to the observations in an expeditious manner

AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis

Open a printable version of this pageEmail the URL of this page to a friend

Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines

Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies

Evotech and Variant Bio partner to develop fibrosis treatment

Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program

Marksans Pharma updates on USFDA inspection at Verna, Goa manufacturing facility

Akums launches Bharosa campaign

The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry

USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria

NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections